Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01320514
Other study ID # Endoscopic Browlift
Secondary ID
Status Recruiting
Phase N/A
First received November 30, 2010
Last updated March 19, 2011
Start date December 2010
Est. completion date May 2011

Study information

Verified date March 2011
Source Nguyen, Davis B., M.D.
Contact Davis B Nguyen, MD
Phone 310 550 0288
Email nguyendavisb@yahoo.com
Is FDA regulated No
Health authority United States: WIRB
Study type Observational

Clinical Trial Summary

The primary objective is to evaluate the safety and efficacy of Artiss (Fibrin Sealant) in reducing the incidence of early postoperative bruising and swelling.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Subjects planned for endoscopic browlift, subjects who read, understand and sign the written informed consent, healthy female or male subjects, 18-75 years old, and subjects who are able and willing to comply with the protocal requirements

Exclusion Criteria:

- Subjects who had previous browlift, subjects indicated for concurrent facial surgeries, subjects considered to be active smokers, subjects with ecchymosis/edema on day 0, significant laboratory abnormalities, subjects with known bleeding or coagulation disorders, subjects treated with anti-coagulants.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Compare Ecchymosis and Edema for Fibrin Sealant and no Fibrin Sealant
  • Ecchymosis

Intervention

Drug:
Fibrin Sealant (Artiss)


Locations

Country Name City State
United States Davis B Nguyen, M.D. Beverly Hills California

Sponsors (2)

Lead Sponsor Collaborator
Nguyen, Davis B., M.D. Baxter BioScience

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of ecchymosis and edema 30 days No
Secondary Resolution of ecchymosis and edema, incidence of hematoma/seroma 30 days No